Podcast Atlas
Source note Episode guide Original audio Topics: Economics, Politics

Vol.275 澳洲保健品是怎么火起来的？

Summary

This 商业就是这样 episode asks why Chinese consumers treat Australian supplements as a category they trust, and answers with four layers: a long Australian tradition of self-medication, pharmacy compounding, naturopathy, and health-food retail; an industrial base in which contract manufacturers turned concepts into sellable products; a therapeutic-goods regime that regulates manufacturing and labelling but not efficacy; and a marketing machine that pushed brands into fast-moving-consumer-goods territory before Chinese cross-border channels carried them into the mainland market. The source’s conclusion is that “Australian supplements are good” is a constructed common sense assembled from real historical soil, successful local brand stories, and a very strong distribution push, with the efficacy question left largely unsupervised.

Key Claims

  • Australia’s supplement industry grew out of practical self-care rather than a designed industrial policy: sparse colonial settlement and long distances from doctors produced self-medication habits, pharmacists who compounded and prescribed in ways that overlapped with physicians, a European-derived naturopathy movement with Australian professional organisations by the 1920s, and health-food shops that the hosts compare to Chinese 食补 traditions.
  • 澳佳宝 is the source’s example of that tradition becoming a brand. It began as a naturopathic clinic and consultation business that also ran one of Australia’s earliest health-food stores, and the second generation translated “too mystical” naturopathy into mainstream-recognisable products through research collaborations and university partnerships while still selling through naturopathy-centred stores; the hosts liken the move to the modernisation of Chinese medicine.
  • Vitamins industrialised from the 1930s onward, when individual vitamins were isolated, identified, and shifted from natural to synthetic forms, and by the 1940s U.S. brands such as One A Day had made the multivitamin a standardised industrial product. Australia built supplements as industrial products too, but the process was slow rather than planned.
  • Contract manufacturing is the source’s key capability layer. Pan Pharmaceuticals, founded in 1974 as a supplement-only contract manufacturer, was later reported to have produced around 70% of Australia’s vitamin, mineral, and herbal output by about 2003, and each dose form - tablets, compound ingredients, soft gels, powders, liquids - carries its own process and stability problems.
  • The industry moved from CMO to CDMO work: first-generation outsourcing was pure manufacturing, and 1980s-90s contract manufacturers extended into formulation, raw materials, labelling, packaging, testing, product registration, and export. A brand can therefore supply only a concept, which the hosts compare to Chinese beauty brands and the Shenzhen hardware supply chain.
  • TGA regulation looks drug-like but separates listed and registered tracks. Most supplements enter the listed AUSTL track, which allows only permitted low-risk ingredients and low-level permitted claims, requires the company to apply for its own number, and receives no pre-market review but some post-market sampling. Higher-risk products enter the registered AUSTR track with pre-market safety, quality, and efficacy assessment; the source’s calcium example gives ordinary strength an “L” number and high-concentration calcium an “R” number.
  • The source says Australia had roughly 10,000 complementary medicines by around 2010 and that nearly 98% were listed rather than registered, and it relays TGA advice that consumers should tell hospital staff about supplement use because supplement ingredients act on the body.
  • GMP guarantees process rather than benefit. It requires product-description consistency, batch-to-batch stability, process tracing, and recall capability, and it narrows quality gaps between contract manufacturers so brands can switch factories more easily - but the brand, not the regulator, is responsible for the efficacy claims filed with the TGA.
  • The hosts’ summary judgment is that the Australian system is strict in appearance and loose in practice. Saying Australia “regulates supplements as medicines” is not exactly wrong, but it is misleading because the gap between supplement and drug oversight is widest on efficacy.
  • 斯维斯 is the source’s marketing case. Founded in 1969 from a Melbourne organic bakery with pollen tablets as its first product, it launched a women’s multivitamin in 1991 and a men’s multivitamin in 1995; the hosts argue that gendered segmentation is psychological targeting rather than a meaningful product difference, and that the American “one a day” template and later age- and life-stage segmentation already existed.
  • After 2008 a new Swisse CEO copied what worked for Centrum/善存 - year-round television advertising, athlete endorsements, and consumers asking for the brand by name - but first misread the audience by buying men’s cricket coverage for a channel whose buyers skew female. Moving to spoken placements in the dance and variety shows mothers watch, then to Oprah, Ellen, and Nicole Kidman, shifted the brand from Australian pharmacy shelves toward the United States.
  • By 2012 the source reports 25 brand ambassadors, more than 80 television advertisements in the previous 12 months, roughly EUR 183 million of annual revenue, EUR 40-50 million of annual marketing spending, and a claim that Swisse was briefly Australia’s heaviest-spending consumer brand, alongside more than 20% supermarket share and close to 10% pharmacy share.
  • The episode reads that spending as an up-cycle strategy: the marketing sold an energetic, self-disciplined, good-looking lifestyle rather than an ingredient, and the same high-spend logic has since become much harder to sustain as returns fall, while Chinese competitors lean on ingredient-literacy (“成分党”) storytelling instead.
  • Adjacent categories are drifting into supplement ingredients. Collagen and probiotics now appear in cosmetics, snacks, drinks, and milk tea because going through China’s health-food registration is far harder than adding an ingredient to food, and new permitted function descriptions create new demand - the source cites the addition of “helps maintain bone and joint health” to the permitted list and the resulting boom in glucosamine products.
  • Marketing intensity is the source’s explanation for the category’s economics: Swisse once spent about a quarter of revenue on advertising, while 汤臣倍健’s 2026 half-year report is described as showing a 42% selling-expense ratio with revenue and profit growth lagging that spending, which supports the claim that the category has no hard entry barrier and that marketing is the main competition.
  • 代购 was the accidental channel. After an underwhelming U.S. push, Swisse found that pharmacies in Chinese-Australian districts sold roughly ten times as much as ordinary stores because students and migrants bought in bulk to take home or resell online; supplements were an early overseas-purchasing staple alongside infant formula, and platforms later displaced much of the person-to-person grey market by running purchasing operations themselves.
  • The 2015 policy window industrialised that flow. Hangzhou’s cross-border e-commerce comprehensive pilot zone was approved in March and the China-Australia free trade agreement was signed in June and took effect in December; the agreement mainly served general trade, where the source puts vitamin and supplement tariffs at 3-10% by Australian official statistics and an average of about 20% by 澳佳宝’s own estimate, scheduled to fall to zero within four years.
  • Bonded warehouses were the operational mechanism: platforms bought overseas goods in bulk into domestic warehouses, shipped on order, accepted a small tax, cut logistics time and cost, and - most importantly - sold goods classified as personal-use items, so supplements skipped ordinary import and registration requirements. The hosts say many Chinese consumers first met Swisse and Blackmores in that bonded-warehouse era.
  • Ownership has since changed without changing the story. 合生元 acquired control of Swisse in September 2015 and full ownership two years later, at a reported deal size of about AUD 1.7 billion or RMB 8.7 billion, and the combined company is now 健合集团; the source argues the price was not generous for Swisse but good for the buyer, because most of the value sits in brand goodwill that consumers can still read as Australian.
  • The episode refuses a single answer to whether Australian supplements are “good.” It separates manufacturing reliability, listed-company status, company age, advertising visibility, and actual ingredient effect, and it describes the consumer inference chain - sold in Australian pharmacies, therefore strictly regulated, therefore effective, therefore worth buying, therefore Australia is unusually good at this - as reasonable but saturated with unverified “shoulds.”
  • The closing frame is Inception: a belief takes hold when it fits factual logic, comes with persuasive successes such as Blackmores and Swisse, and is delivered by a very strong mechanism, which Chinese cross-border e-commerce supplied over the past decade. Simple conclusions are easier to remember than the layered reasoning behind them.

Key Quotes

“看上去严格、实际上宽松” - the hosts’ summary of a system that polices process while leaving efficacy to the brand.

“把保健品当药管” - the popular claim the episode calls not wrong but misleading.

“每天吃一勺鱼油” - the household habit used to explain how folk practice becomes a standardised product.

“越像常识的商业概念，越值得多问一句它是怎么来的” - the closing methodological warning.

Connections

Contradictions

  • No settled contradiction found with existing wiki content. The source complements the U.S.-centred Dietary Supplement Regulation and Supplement Structure Function Claims pages with an Australian regime that is stricter in manufacturing and claims vocabulary but equally permissive on efficacy.
  • The source qualifies Constructed Category Trust / 被建构的品类信任’s origin-country logic by separating brand capacity (brands, manufacturing, regulation theatre) from product efficacy, which the episode says is verified at no stage before sale.
  • The source qualifies Cross-Border Ecommerce Localization Pressure / 跨境电商本地化压力 by showing the older bonded-warehouse route, where goods shipped as personal-use items avoided exactly the local registration that localization pressure later forces.
  • Source-scope warning: the transcript is a speech-to-text product with visible name damage. The wiki normalises 斯维斯/思维师 to Swisse / 斯维斯, 澳家宝/Black Moss to 澳佳宝, 和声园 to 合生元, and 建和集团 to 健合集团; treated figures such as Pan Pharmaceuticals’ roughly 70% output share, the roughly 10,000 complementary medicines and 98% listed share, Swisse’s revenue, ambassador count, advertisement count, marketing spend, market shares, the roughly AUD 1.7 billion deal size, Blackmores’ 20% average tariff estimate, and 汤臣倍健’s 42% selling-expense ratio remain source-scoped rather than independently verified.